Inhibition of ALK1 function using a neutralizing antibody or an ALK1‐Fc ligand trap (dalatracept) resulted in a minor therapeutic response as single agent in phase 2 clinical trials in cancer patients (Table 1) 145, 146, 147. The gene discussed is ACVRL1; the disease is cancer.